Table 1 Baseline characteristics of the population according divided according to dose of NOACs at first prescription in AIFA Registry.
Standard dose | Reduced dose | Overall | |
|---|---|---|---|
N° treatments | 507,548 (54.72%) | 419,975 (45.28%) | 927,523 (100.00%) |
Sex | |||
Female | 223,266 (43.99%) | 239,511 (57.03%) | 462,777 (49.89%) |
Male | 284,282 (56.01%) | 180,464 (42.97%) | 464,746 (50.11%) |
Median age (range) | 74 (18–102) | 83 (18–109) | 78 (18–109) |
Age < 65 | 87,692 (17.28%) | 9821 (2.34%) | 97,513 (10.51%) |
Age ≥ 65 and < 75 | 190,581 (37.55%) | 45,943 (10.94%) | 236,524 (25.5%) |
Age ≥ 75 and < 85 | 194,718 (38.36%) | 209,268 (49.83%) | 403,986 (43.56%) |
Age ≥ 85 | 34,557 (6.81%) | 154,943 (36.89%) | 189,500 (20.43%) |
CHA2DS2-VASc Score 0 | 5791 (1.14%) | 442 (0.11%) | 6233 (0.67%) |
CHA2DS2-VASc Score 1 | 33,827 (6.66%) | 2954 (0.7%) | 36,781 (3.97%) |
CHA2DS2-VASc Score 2 | 87,059 (17.15%) | 18,062 (4.3%) | 105,121 (11.33%) |
CHA2DS2-VASc Score 3 | 131,845 (25.98%) | 70,404 (16.76%) | 202,249 (21.81%) |
CHA2DS2-VASc Score 4 | 124,502 (24.53%) | 131,198 (31.24%) | 255,700 (27.57%) |
CHA2DS2-VASc Score 5 | 71,059 (14%) | 101,016 (24.05%) | 172,075 (18.55%) |
CHA2DS2-VASc Score 6 + | 53,465 (10.53%) | 95,899 (22.83%) | 149,364 (16.1%) |
HAS-BLED Score 0 | 16,554 (3.26%) | 1356 (0.32%) | 17,910 (1.93%) |
HAS-BLED Score 1 | 93,919 (18.5%) | 39,652 (9.44%) | 133,571 (14.4%) |
HAS-BLED Score 2 | 212,818 (41.93%) | 165,812 (39.48%) | 378,630 (40.82%) |
HAS-BLED Score 3 | 123,757 (24.38%) | 128,434 (30.58%) | 252,191 (27.19%) |
HAS-BLED Score 4 + | 60,500 (11.92%) | 84,721 (20.17%) | 145,221 (15.66%) |
Diabetes history | 98,032 (19.31%) | 84,054 (20.01%) | 182,086 (19.63%) |
Hypertension history | 434,300 (85.57%) | 365,327 (86.99%) | 799,627 (86.21%) |
Stroke/TIA/Thromboembolism history | 79,712 (15.71%) | 82,912 (19.74%) | 162,624 (17.53%) |
Vascular disease history | 122,184 (24.07%) | 128,483 (30.59%) | 250,667 (27.03%) |
CHF history | 115,797 (22.81%) | 148,397 (35.33%) | 264,194 (28.48%) |
Alcohol use | 28,231 (5.56%) | 17,525 (4.17%) | 45,756 (4.93%) |
Liver disease | 3889 (0.77%) | 4880 (1.16%) | 8769 (0.95%) |
Renala disease | 8122 (1.6%) | 42,920 (10.22%) | 51,042 (5.5%) |
Prior major bleeding or predisposition to bleeding | 41,317 (8.14%) | 61,880 (14.73%) | 103,197 (11.13%) |
Labile INR | 108,349 (21.35%) | 87,797 (20.91%) | 196,146 (21.15%) |
Prior anticoagulant treatment (AVK) | 152,638 (30.07%) | 119,824 (28.53%) | 272,462 (29.38%) |
Medication usage predisposing to bleeding | 73,221 (14.43%) | 80,020 (19.05%) | 153,241 (16.52%) |
Prior NOAC treatment (switch) | 28,520 (5.62%) | 32,210 (7.67%) | 60,730 (6.55%) |
